ReviewMolecules (Basel, Switzerland)2025
Expanding the Terpene Universe: Synthetic Biology and Non-Natural Chemistry in Engineered Microorganisms.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic Engineering for Gibberellic Acid Production inMolecules (Basel, Switzerland) · 2026Review
- Strategic selection of microbial cell factories for sustainable and application-specific terpenoid production.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Terpenes, representing one of the most extensive classes of natural products, hold significant value in the fields of pharmaceuticals, fragrances, and biofuels. Extracting these compounds from natural sources is often environmentally unsustainable, and the structural diversity found in nature is inherently limited. Metabolic engineering using microbial hosts offers a scalable and sustainable alternative, utilizing optimized biosynthetic pathways-such as the mevalonate (MVA) and the methylerythritol phosphate (MEP) pathways-to achieve high-yield production of natural terpene scaffolds. This review focuses on the various strategies in developing microbial cell factories, ranging from enhancing precursor supply to optimizing terpene synthase systems. A new and promising frontier is the increase in structural diversity of terpenes by integration of non-biological chemical transformations into engineered biosynthetic pathways. We discuss the use of artificial metalloenzymes such as engineered cytochrome P450 variants that catalyze non-natural carbene transfer reactions (cyclopropanation). The merging of synthetic biology and synthetic chemistry goes beyond the normal synthesizing capabilities found in nature, which may pave the way for the design of "non-natural" terpenoids that contain new additions and better capabilities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.